| Literature DB >> 34195031 |
Wan-Yu Lo1, Chung-Hsiang Liu2, Chao-Hsiang Chen3,4, Ching-Liang Hsieh5,6,7.
Abstract
BACKGROUND AND AIM: Astragalus membranaceus (AM) is a major Chinese herb used in the treatment of stroke. Astragaloside IV (AS)is a component of AM. This study investigated the effects of AM on the protein expression through proteomics analysis in ischemia-reperfusion injured Sprague Dawley rats. EXPERIMENTAL PROCEDURE: An animal model of ischemia-reperfusion injury by occlusion of the right middle cerebral artery for 90 min followed by reperfusion for 24 h. The rats were intraperitoneally injected with AM or AS three times at 30 min, 1 day, and 2 days prior to the occlusion of the cerebral blood flow.Entities:
Keywords: Astragaloside IV; Astragalus membranaceus; Brain tissue; Ischemia-reperfusion injury; Protein biomarker
Year: 2021 PMID: 34195031 PMCID: PMC8240166 DOI: 10.1016/j.jtcme.2021.04.002
Source DB: PubMed Journal: J Tradit Complement Med ISSN: 2225-4110
Q-TOF mass spectrum data and database searching for protein identification in the frontal cortex and hippocampus.
| Protein ID | Accession No. | Experimental Mr (kDa)/pI | Theoretical Mr (kDa)/pI | Sequence coverage | Gene expression |
|---|---|---|---|---|---|
| EEF1B2 | B5DEN5 | Mr = 37 kDa; pI = 5.6 | Mr = 24.8 kDa; pI = 4.6 | 35.3% | AM>(Sham>2 fold C) |
| CORO1A | Mr = 56 kDa; pI = 6.4 | Mr = 55.4 kDa; pI = 6.1 | 21.2% | AM>(Sham>2 fold C) | |
| TPI1 | Mr = 26 kDa; pI = 6.3 | Mr = 26.8 kDa; pI = 6.9 | 24.6% | AM>(Sham>2 fold C) | |
| ALDOC | Mr = 39 kDa; pI = 6.8 | Mr = 39.3 kDa; pI = 6.7 | 16.2% | AM & AS >(Sham>2 fold C) | |
| DLD | Mr = 45.8 kDa; pI = 6.8 | Mr = 54 kDa; pI = 7.96 | 30.4% | AM & AS >(Sham>2 fold C) | |
| TPI1 | Mr = 26.5 kDa; pI = 7.0 | Mr = 26.8 kDa; pI = 6.9 | 17.5% | AM & AS >(Sham>2 fold C) | |
| SYN2 | Mr = 65.5 kDa; pI = 8.0 | Mr = 63.4 kDa; pI = 8.7 | 12.3% | AM> (Sham>2 fold C) | |
EEF1B2: Eukaryotic translation elongation factor 1 beta 2; CORO1A: Coronin 1A; TPI1: Triose-phosphate isomerase; ALDOC: Aldolase C; DLD: Dihydrolipoamide dehydrogenase; SYN2: Synapsin II; AM: AM group; AS: AS group; Sham: sham group; C: control group.
Fig. 1Images of frontal cortex and hippocampus fractions of the sham group separated using 2-DE and stained with silver nitrate. A: Spots 1, 2, 3, and 4 were matched and identified as Eukaryotic translation elongation factor 1 beta 2 (EEF1B2), Coronin 1A (CORO1A), Triose-phosphate isomerase (TPI1), and Aldolase C (ALDOC), respectively, through nano- LC-MS/MS. B: Spots 5, 6, and 7 were matched and identified as Dihydrolipoamide dehydrogenase (DLD), TPI1, and Synapsin II (Syn2), respectively, through nano-LC- MS/MS.
Fig. 2Dynamic results of real-time quantitative-PCR (real-time Q-PCR) analysis in the cortex. Compared with the sham group, only Coronin 1A (CORO1A) was overexpressed by an average of 1.45-fold in the AM group. Compared with the AM group, only Aldolase C (ALDOC) was overexpressed in the AS group; C: control group; Sham: sham group; AM: Astragalus membraneus group; AS: Astraloside IV group; ∗, significantly overexpressed compared with the sham group; #, significantly overexpressed compared with the AS group.
Fig. 3Dynamic results of real-time Q-PCR analysis in the hippocampus. Compared with the sham group, only Triose-phosphate isomerase (TPI1) was overexpressed by an average of 1.73-fold in the AM group; C: control group; Sham: sham group; AM: Astragalus membraneus group; AS: Astraloside IV group. ∗, significantly overexpressed compared with the sham group.